Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of the Oncoxin-Viusid® Oral Solution in Reducing the Adverse Reactions of Chemotherapy and Radiotherapy in Patients Diagnosed With Cervical Cancer and Endometrial Adenocarcinoma.

NCT03540407 is registered in ClinicalTrials.gov with Catalysis SL as lead sponsor.

NCT NCT03540407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03540407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of the Oncoxin-Viusid® Oral Solution in Reducing the Adverse Reactions of Chemotherapy and Radiotherapy in Patients Diagnosed With Cervical Cancer and Endometrial Adenocarcinoma.
Lead sponsor
Catalysis SL
Phase
Phase 2
Overall status
Completed
Start date
January 7, 2015
Completion date
September 30, 2019
Enrollment
66 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical carcinoma stage ii, cervical carcinoma stage iii, cervical carcinoma stage iv, endometrial adenocarcinoma stage ii, endometrial adenocarcinoma stage iii, endometrial adenocarcinoma stage iv